We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LSGPA Invests $250,000 in SoftGenetics
News

LSGPA Invests $250,000 in SoftGenetics

LSGPA Invests $250,000 in SoftGenetics
News

LSGPA Invests $250,000 in SoftGenetics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "LSGPA Invests $250,000 in SoftGenetics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) has announced an investment of $250,000 in SoftGenetics, LLC.

The funds will be used to accelerate development of the company's "MicroArray Copy Number and SNP Chip" software.

It's widely believed that the ability to pinpoint variation in SNPs is the first step toward identifying susceptibility to or causes of certain diseases.

"If the promise of personalized medicine is to be realized, today's researchers and diagnosticians need access to highly sensitive, highly accurate tools that are also fast and easy to use," says SoftGenetics V.P. of Development, Dr. C.S. Liu.

"With this funding we intend to leverage our existing expertise in mutation detection and software design to deliver to the research and medical communities precisely the tool they've been clamoring for."

Dr. Mel Billingsley, President & CEO of LSGPA, noted that the importance of genetics-based diagnosis and treatments has been on the rise as the human genome has been sequenced.

"As both a researcher and an investor, it's exciting to be involved with a company working at the confluence of information technology and healthcare."

"The scientific community has just begun to exploit the potential of molecular diagnostics, but we can be certain that the field will have significant impact on the quality of patient care."

Advertisement